Ozon Medica

History

2025: Completion of monolithic work on the construction of the first stage of the enterprise

In accordance with the schedule, Ozone Pharmaceuticals completed the next stage of construction of the Ozone Medica production site in the special economic zone of Togliatti. By the end of 2024, monolithic work in the main production building (GPK) was fully completed, the basis for the installation of the roof and walls was prepared. During 2025, it is planned to complete civil and finishing work at the MSH, as well as the installation and launch of process equipment and clean rooms. Site licensing is scheduled for 2026. The company announced this on January 30, 2025.

In the perimeter of the Group, Ozone Medica is responsible for the development and production of drugs against cancer and severe systemic autoimmune diseases. Highly toxic drugs of the Ozone Medica portfolio require for the production not just separate equipment or a dedicated area, but a separate production complex.

Construction of the plant was started at the end of 2023. The total area of ​ ​ the main production building "Ozone Medica" will be 25 thousand m ². The first stage of construction of the MSH includes a production area of ​ ​ solid non-sterile dosage forms with an area of ​ ​ 840 m2, 2 thousand m2 of storage facilities, laboratories, a first-aid post and personnel rooms.

Within the framework of the Ozone Medica project, it is planned to launch three production sites with two autonomous production buildings and isolated air and water treatment systems. Manufacturing capabilities will cover the release of solid non-sterile medicinal products (hard gelatin capsules, coated and uncoated tablets), as well as solid and liquid sterile medicinal products (lyophilisates and solutions/concentrates for injection in vials).

Commercial production is planned to be launched in 2027. As of January 2025, Ozon Medica LLC owns 21 registration certificates for antitumor drugs. With the start of commercial production and the expansion of the Ozone Medica portfolio, the Group expects to increase sales volumes in the direction of public procurement, which in the first 9 months of 2024 amounted to 22% of the Group's gross revenue.

2024: Construction of a plant for the production of cancer drugs in the SEZ of Togliatti for 3.5 billion rubles

The Group, a Ozone Pharmaceuticals Russian pharmaceutical manufacturer of drugs, has completed the first stage constructions of the Ozone Medica production site in the special economic zone. Representatives Togliatti of the Group reported this medical that to the portal Zdrav.Expert on July 30, 2024. According to them, the plant will have wide possibilities for the production of pharmaceutical forms, including the production of drugs of the maximum, fifth, toxicity category.

𝓲

Фото: Freepik

Construction of the production site began at the end of 2023. The area of ​ ​ the plant will be 25 thousand m ². Licensing is scheduled for early 2026. It is planned to fully complete construction and launch production in 2027. According to the company's estimates, investments in the construction of the building and the first production site "Ozone Medica" will amount to more than 3.5 billion rubles, of which 1.1 billion the Group has already invested.

Ozone Medica is responsible for the development and subsequent production of drugs against oncology and severe systemic autoimmune diseases. As of the end of July 2024, Ozon Medica LLC owns 18 registration certificates and plans to multiply the portfolio as part of the Group's strategy for further development in chemical pharmaceuticals and biotech. With the expansion of the Ozone Medica portfolio, the Group expects to increase sales volumes in the direction of public procurement, which in 2023 amounted to 20% of the Group's total revenue.

According to Ozone Pharmaceuticals, the products of the Ozone Medica portfolio will be divided into sections, taking into account the form of production, toxicity and belonging to special groups requiring dedicated production.

Three production sites are planned for the release of cytostatics and cytotoxics. Manufacturing capabilities will cover the release of solid non-sterile medicinal products (hard gelatin capsules, coated and uncoated tablets), as well as solid and liquid sterile medicinal products (lyophilisates and solutions/concentrates for injection in vials).

"Ozone Pharmaceuticals Group" is one of the largest investors operating in the Samara region. The fact that the company is expanding its presence in the Togliatti Special Economic Zone, implementing the project of a drug production plant, once again speaks of the high efficiency of the investment policy implemented in our region, "said Vyacheslav Fedorishchev, Acting Governor of the Samara Region. "The first stage of the construction of the plant has been completed, and this is certainly an important step in solving the task set by the head of state Vladimir Vladimirovich Putin to increase the share of domestic drugs in the Russian market, to ensure the independence of our healthcare system from foreign pharmaceutical suppliers."